FIGURE 3 HERE
Figure 3. Pathways identified
that support montelukast repurposing. A. Molecular basis of
Alzheimer’s disease. Amyloid precursor protein (APP) can be processed
through a non-amyloidogenic pathway, where it is cleaved by α- and
γ-secretases, or through an amyloidogenic pathway, where it is cleaved
by β- and γ-secretases, leading to the formation of Aβ peptides (Chenet al. , 2017; De Strooper et al. , 2010). Aβ peptides can
then undergo clearance (or degradation) processes within the brain or
after transport from the brain to the periphery (liver and kidney).
These processes include proteolytic pathways that depend on neprilysin
(NE), insulin-degrading enzyme (IDE), matrix metalloproteinases (MMPs),
angiotensin-converting enzyme (ACE), endothelin-converting enzyme (ECE),
plasmin, the activity of the ubiquitin-proteosome system, the
autophagy-lysosome system, or microglial phagocytosis (Nalivaeva and
Turner, 2019; Xin et al. , 2018). Image adapted from Marqueset al. (2022c). B. Energy producing glycolytic pathway
and tricarboxylic acid cycle (Yan et al. , 2020). Enzymes marked
in red represent the MTK-altered proteins. Created with BioRender.com.